{
    "2021-12-23": [
        [
            {
                "time": "2023-10-01",
                "original_text": "'Unmovable monster': The drug trial that changed how biotechs approach rare disease treatments",
                "features": {
                    "keywords": [
                        "drug trial",
                        "biotechs",
                        "rare disease",
                        "treatments"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion",
                "features": {
                    "keywords": [
                        "Novartis",
                        "FDA",
                        "Cosentyx",
                        "label expansion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis' Cosentyx Scores FDA Approval For Arthritis In Children, Adolescents",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Cosentyx",
                        "FDA",
                        "arthritis",
                        "children",
                        "adolescents"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol",
                "features": {
                    "keywords": [
                        "FDA",
                        "Alnylam",
                        "Novartis",
                        "Leqvio",
                        "siRNA",
                        "bad cholesterol"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis Eyes Up to $1.5 Billion for Gene Therapy Firm",
                "features": {
                    "keywords": [
                        "Novartis",
                        "gene therapy",
                        "firm",
                        "$1.5 billion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}